Immune checkpoint inhibitors (ICIs) have yielded remarkable responses but often lead to
immune-related adverse events (irAEs). Although germline causes for irAEs have been …

The immune checkpoint inhibitor (ICI) pembrolizumab is US FDA approved for treatment of
solid tumors with high tumor mutational burden (TMB-high; ≥10 variants/Mb). However, the …

We study the effects of integrability-breaking perturbations on the nonequilibrium evolution of
many-particle quantum systems. We focus on a class of spinless fermion models with weak …

Abstract Treatment with immune checkpoint blockade (ICB) frequently triggers immune-related
adverse events (irAEs), causing considerable morbidity. In 214 patients receiving ICB for …

Background Predictive biomarkers could allow more precise use of immune checkpoint
inhibitors (ICIs) in treating advanced cancers. Given the central role of HLA molecules in …

Purpose: Genetic differences in immunity may contribute to toxicity and outcomes with
immune checkpoint inhibitor (CPI) therapy, but these relationships are poorly understood. We …

We employ equation-of-motion techniques to study the nonequilibrium dynamics in a lattice
model of weakly interacting spinless fermions. Our model provides a simple setting for …

We consider the full probability distribution for the transverse magnetization of a finite
subsystem in the transverse field Ising chain. We derive a determinant representation of the …

Background Hundreds of thousands of cancer patients have had targeted (panel) tumor
sequencing to identify clinically meaningful mutations. In addition to improving patient outcomes, …

Many genetic variants affect disease risk by altering context-dependent gene regulation.
Such variants are difficult to study mechanistically using current methods that link genetic …